This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Investigating the Phase 2 AAVIATE clinical trial of ABBV-RGX-314 in patients with Wet AMD.
Ticker(s): RGNX, ABBVWho's the expert?
Institution: CHA Medical Group
- Currently manages over 500 wet AMD patients and 500 Geographic Atrophy patients.
- Primary focus on novel approaches to cataract surgery, glaucoma, dry eye, diabetic retinopathy, and other corneal surface disease.
- Specializes in relationships between various eye care professionals (Optometry and Ophthalmology), and insurance for the eye space.
Interview Goalto discuss the treatment landscape and the potential of ABBV-RGX-314, a gene therapy being developed by REGENXBIO and AbbVie for the treatment of Wet AMD.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
